Compare Consolidated Edison, Inc. (ED) vs InMode Ltd (INMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs InMode Ltd — how do they compare? Consolidated Edison, Inc. trades at $106.11 (market cap $39.20B), while InMode Ltd trades at $14.22 (market cap $809.93M). The key difference: Consolidated Edison, Inc. is far larger — about 48.4× InMode Ltd's market cap, and Consolidated Edison, Inc. pays a 3.31% dividend while InMode Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and InMode Ltd for 28 Days on average.
| ED | INMD | |
|---|---|---|
Market Cap | $39.20B | $809.93M |
Volume | 2,142,900 | 365,490 |
Sector | Utilities | Health |
52-Week High | $115.46 | $16.62 |
52-Week Low | $95.37 | $12.76 |
Typical Hold Time | 75 Days | 28 Days |
Enterprise Value | $66.05B | $313.27M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $106.10, up 1.39% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The stock's valuation appears reasonable with a P/E of 17.43 and P/S of 2.18, while profitability metrics like a 12.53% net income margin and 8.96% ROE reflect steady utility performance. Recent earnings showed beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains strong cash flow from operations of $4.80 billion in 2025 and continues its dividend aristocrat status with a recent $0.89 dividend declaration.
ED offers stable income appeal with a solid dividend history, supported by regulated utility operations and a $24.8 billion economic impact in New York. However, high debt levels ($24.65 billion long-term) and modest growth prospects pose risks. Analyst sentiment is cautious with 62.96% hold ratings, though the consensus price target of $106.33 aligns with the current price, suggesting limited near-term upside amid economic sensitivity.
INMD trades at $14.20, up 1.36% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with 76.52% gross margins and 20.69% net income margin, though Q1 2026 earnings missed expectations. Recent news includes product innovation with Morpheus8 Cool launch and an unsolicited acquisition offer from Steel Partners at $16.75 per share. Analyst consensus is divided with 45% buy ratings amid ongoing shareholder activism concerns.
The stock presents value opportunity with attractive valuation multiples (P/E 11.63, EV/EBITDA 4.48) but faces near-term execution risks. Key catalysts include Q3 earnings delivery and resolution of acquisition talks, while risks involve management credibility and competitive pressures in aesthetic medicine markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
